Shore Capital Reiterates Buy Rating for Uniphar (LON:UPR)

Uniphar (LON:UPR)‘s stock had its “buy” rating reiterated by analysts at Shore Capital in a research note issued on Tuesday,London Stock Exchange reports.

Uniphar Stock Performance

Uniphar stock traded up GBX 17 ($0.21) during midday trading on Tuesday, reaching GBX 195 ($2.43). 48,700 shares of the company’s stock were exchanged, compared to its average volume of 20,728. Uniphar has a 52 week low of GBX 163 ($2.03) and a 52 week high of GBX 256 ($3.19). The company has a debt-to-equity ratio of 119.43, a quick ratio of 0.60 and a current ratio of 0.90. The firm has a market cap of £532.39 million, a price-to-earnings ratio of 1,392.86 and a beta of 0.75. The stock’s 50-day simple moving average is GBX 174.62 and its 200 day simple moving average is GBX 198.80.

Uniphar Company Profile

Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology
manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.